Actual More Than 10 Years Survivor after Ultrasound-Guided Percutanouse Microwave Ablation for Hepatocellular Carcinoma
Xin Li,Chao An,Zhigang Cheng,Xiaoling Yu,Zhiyu Han,Fangyi Lu,Jie Yu,Ping Liang
DOI: https://doi.org/10.2139/ssrn.3378682
2019-01-01
SSRN Electronic Journal
Abstract:Background: We aimed to evaluate the risk factors of survival outcome after US-guided percutaneous microwave ablation (US-PMWA) for HCC patients with more than 10 years follow-up period.Methods: A single center study from China involving treatment-naive HCC patients met the Milan criteria who received US-PMWA between April 2002 and October 2008. As validation, 130 HCC patients were screened out from 373 ones, and the data was analyzed. Thirty-three patients survived more than 10 years, and 97 less. Univariate analysis was assessed by the Kaplan-Meier method with log-rank test. Cox proportional hazard regression model based on risk factors for OS in HCC patients after US-PMWA was used to construct the nomogram.Findings: The median time of RFS and OS were 2.1 and 7.9 years, respectively. The 1, 3, 5, and 10-year RFS and OS rates were 75.3%, 41.2%, 32.5% and 23.1%, and 90.9%, 68.0%, 61.1% and 25.4, respectively. Univariate analysis showed that age (P=0.002), comorbidities (P=0.016), CTP grade (P=0.036) and preoperative TACE (P=0.023) were risk factors for OS, and multivariate analysis results showed that age (≥65 years) (P=0.004, HR 2.005, 95%CI 1.251-3.212), comorbidities (P<0.001, HR 0.600, 95%CI 0.494-0.727) and early recurrence (P=0.025, HR 1.717, 95%CI 1.070-2.754) were independently associated with poor OS. The nomograms were developed on the basis of above variables. Internal validation had good concordance index of 0.769 (95%CI 0.699, 0.839) in OS.Interpretation: The results suggest that early HCC patients with younger age, no comorbidities and late/no recurrence would be benefit to more than 10 years survival after US-PMWA. Fund: This work was supported by the National Key R&D Program of China (No. 2017YFC0112000), three grants 81430039, 81627803 and 81801723 from the National Scientific Foundation Committee of China; 2017FC-CXYY-3005 from the Clinical Research Support Foundation of the Chinese PLA General Hospital.Funding Statement: This work was supported by the National Key R&D Program of China (No. 2017YFC0112000), three grants 81430039, 81627803 and 81801723 from the National Scientific Foundation Committee of China; 2017FC-CXYY-3005 from the Clinical Research Support Foundation of the Chinese PLA General Hospital.Declaration of Interests: The authors declare no conflict of interest.Ethics Approval Statement: Written informed consent was obtained from each enrolled patient, and the protocol was approved by the Institutional Ethics Committee.